Salute e Benessere
New TriNetX Survey Reveals Biopharma's Bold Embrace of Real-World Data and Artificial Intelligence--But Warns of Looming Barriers
The survey, which polled 150 senior executives across pharma and biotech, found that:
"Real-world data is no longer a concept, it's a capability," said Steve Kundrot , Chief Operating Officer at TriNetX. "The leaders we surveyed see its value and are investing in execution. But to fully realize real-world data's promise, we must tackle integration challenges, enforce data standards, and build trust in AI applications."
Respondents reported using an average of 5.3 sources of RWD, including lab (77%), genomics (62%), registry (61%), and health equity data (61%). However, data compatibility concerns (29%) emerged as the top barrier to broader use.
To overcome this, Kundrot emphasized the need for data harmonization and semantic alignment: "It's important to find a trusted data partner that can integrate disparate sources across healthcare organizations and geographies while maintaining fidelity and privacy."
The survey confirms a growing industry trend toward inclusive, patient-centric clinical trials:
Still, progress is not without obstacles. Regulatory complexity (36%) and accessibility challenges (34%) are the most cited barriers to broader representation.
"Regulatory uncertainty can stall inclusive trial design, even when the intent is there," said
Jeffrey Brown , PhD, Chief Scientific Officer at TriNetX. "Real-world data, especially social determinants of health, helps uncover patient realities and generate the kind of evidence regulators are looking for. It's the bridge between inclusion goals and regulatory confidence."
In a unanimous vote of confidence, 100% of respondents agreed that RWE can improve regulatory submissions, a milestone for biopharma's evolving evidence generation strategies. Yet, success requires strategic execution.
"You have to ensure real-world data is fit-for-purpose and applied to sensible use cases," noted Brown. "To succeed with regulators, biopharma must ensure data quality, proper study design, and ethical application, especially in rare disease research where new trials may not be feasible."
While AI adoption escalates, 36% of respondents cite data security as a top concern when combining AI with RWD. Kundrot advises organizations to implement strict privacy controls and demand audit rights with AI partners. "AI's potential is enormous," he said, "but without trust and transparency in how data is processed and protected, adoption with falter."
The complete survey findings, commentary from TriNetX experts, and strategic recommendations are now available in the full report: .
TriNetX operates the world's broadest federated network of real-world data in partnership with healthcare providers and applies intelligence that accelerates innovation across the healthcare ecosystem. Through its self-service, HIPAA-, GDPR-, and LGPD-compliant platform of federated deidentified and anonymous electronic health record datasets and consulting partnerships, TriNetX empowers its global community to improve clinical trial protocol design, streamline trial operations, refine safety signals, and enrich real-world evidence generation. For more information, please visit TriNetX at www.trinetx.com or follow TriNetX on LinkedIn.
TriNetX
Karen Tunks
Email: Karen.Tunks@TriNetX.com
Logo - https://mma.prnewswire.com/media/542641/TriNetX_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/new-trinetx-survey-reveals-biopharmas-bold-embrace-of-real-world-data-and-artificial-intelligencebut-warns-of-looming-barriers-302504580.html